Investigational drug · Phase 2
ETD001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cystic Fibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "ETD001"
First trial start
2024
Jun 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ETD001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cystic Fibrosis
Approved drugs for the same conditions: Cystic fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "ETD001" as an intervention, largest first.
Enterprise Therapeutics LtdIndustry
NCT04926701 · 98 participants · Start Jun 11, 2021 · Primary completion Mar 22, 2022
Drug: ETD001 single dose; Placebo single dose and 4 more · For: Cystic Fibrosis
Sites: London, United Kingdom
- Phase II Clinical Study on Preliminary Efficacy and Safety of ETD-001 Gel for Hypertrophic ScarsNot yet recruiting
Etern Therapeutics Wuxi LimitedAcademic, hospital or other
NCT07891416 · 90 participants (planned) · Start Feb 28, 2027 · Primary completion Dec 31, 2027
Drug: ETD-001 gel; ETD-001 gel · For: Hypertrophic Scars
Sites: Shanghai, China
Enterprise Therapeutics LtdIndustry
NCT06478706 · 57 participants · Start Jun 26, 2024 · Primary completion Nov 14, 2025
Drug: ETD001; Placebo · For: Cystic Fibrosis
Sites: Lyon, France; Montpellier, France; Paris, France · 21 sites in all
Etern Therapeutics Wuxi LimitedAcademic, hospital or other
NCT07674862 · 56 participants · Start Mar 16, 2026 · Primary completion Jul 5, 2026
Drug: Dose 1; dose 2 and 1 more · For: Safety Issues
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial.
Russell P, Woodward K, Morris D, et al. · J Cyst Fibros 2026
- Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis.
Danahay H, Gosling M, Fox R, et al. · Eur J Med Chem 2025
- ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo.
Danahay H, McCarthy C, Schofield T, et al. · J Cyst Fibros 2025
Also in development for Cystic Fibrosis
- VX-121D-IVA, CTP-656Phase 33 trials
Vertex Pharmaceuticals · Cystic Fibrosis
- ARCT-032Phase 21 trial
Arcturus Therapeutics, Inc. · Cystic Fibrosis, CFTR Gene Mutation
- CMTX-101Phase 21 trial
Clarametyx Biosciences, Inc. · Persistent Infection, Cystic Fibrosis
- RCT2100Phase 21 trial
ReCode Therapeutics · Cystic Fibrosis
- SPL84Phase 21 trial
SpliSense Ltd. · Cystic Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.